Get the Stockscreener App
1.12
5.88%
-0.07
Nexalin Technology Inc stock is traded at $1.12, with a volume of 52,037.
It is down -5.88% in the last 24 hours and down -11.81% over the past month.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
See More
Previous Close:
$1.19
Open:
$1.16
24h Volume:
52,037
Relative Volume:
0.51
Market Cap:
$21.56M
Revenue:
$128.60K
Net Income/Loss:
$-4.60M
P/E Ratio:
-1.7778
EPS:
-0.63
Net Cash Flow:
$-3.74M
1W Performance:
-10.76%
1M Performance:
-11.81%
6M Performance:
-67.82%
1Y Performance:
+48.36%
1-Day Range:
$1.115
$1.18
1-Week Range:
$1.115
$1.2499
52-Week Range:
$0.591
$4.4899
Nexalin Technology Inc Stock (NXL) Company Profile
Name
Nexalin Technology Inc
Sector
Industry
Phone
(832) 260-0222
Address
1776 YORKTOWN, HOUSTON
Compare NXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
1.12 | 21.56M | 128.60K | -4.60M | -3.74M | -0.63 |
|
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
|
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
86.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.27 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Nexalin Technology Inc Stock (NXL) Latest News
Jane Street Group LLC Buys New Position in Nexalin Technology, Inc. (NASDAQ:NXL) - Defense World
Nexalin Technology closes partial over-allotment option By Investing.com - Investing.com Nigeria
Nexalin Technology closes partial over-allotment option - Investing.com
Nexalin Technology Closes Additional Share Offering - TipRanks
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment - mx.advfn.com
Northern Trust Corp Makes New Investment in Nexalin Technology, Inc. (NASDAQ:NXL) - Defense World
Nexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - IndyStar
Nexalin Technology, Inc.: Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3 - GlobeNewswire
Nexalin Technology, Inc. to Host Investor Webinar Showcasing Innovative Neurostimulation Advances on June 3, 2025 - Nasdaq
Revolutionary Mental Health Tech: Nexalin Unveils Game-Changing Treatment in $537B Market Webinar - Stock Titan
Coming This Week: Get Ready for the ‘Last Wave of Negative News’ on Nvidia Stock - The Globe and Mail
Is This Dependable Growth Stock a Buy Right Now? - The Globe and Mail
Integrated Cyber Solutions Joins NVIDIA Connect Program to Accelerate Development of AI-Driven IC360 Cybersecurity Platform - The Globe and Mail
Clarifai Wins 2025 AI TechAward for Compute Orchestration - The Globe and Mail
Nexalin Technology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Nexalin Technology (NASDAQ:NXL) Shares Up 1.7% – Here’s Why - Defense World
Nexalin Technology slides after pricing $5M stock offering - MSN
Comparing Gadsden Properties (OTCMKTS:GADS) & Nexalin Technology (NASDAQ:NXL) - Defense World
Nexalin Technology Forms Scientific Advisory Board - citybiz
Nexalin Technology (NXL) Enhances Scientific Advisory Board to T - GuruFocus
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data - The Manila Times
Nexalin Technology Reconstitutes Scientific Advisory Board - GlobeNewswire
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data - Stock Titan
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering - Taiwan News
Nexalin Technology, Inc. Closes Public Offering of 3,850,000 Shares at $1.30 Per Share, Raising $5.0 Million - Nasdaq
Brain Tech Pioneer Nexalin Secures $5M Funding: 3.85M Shares at $1.30 in Public Offering - Stock Titan
Nexalin Technology Announces Public Offering Agreement - TipRanks
Form 424B4 Nexalin Technology, Inc. - StreetInsider
Nexalin Gains International Traction - ACCESS Newswire
Nexalin Shares Fall After Pricing of $5 Million Public Offering - marketscreener.com
Nexalin Technology (NXL) Announces Public Stock Offering | NXL S - GuruFocus
Nexalin Technology sets public offering at $1.30 per share - Investing.com Australia
Nexalin Prices 3.85 Mln Public Offering At $1.30/shr; Stock Plunges In Pre-market - Nasdaq
Nexalin Technology sets public offering at $1.30 per share By Investing.com - Investing.com India
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewswire
Nexalin Technology Prices $5 Million Public Offering - marketscreener.com
$5M Public Offering: How Nexalin Plans to Advance Revolutionary Brain Stimulation Technology - Stock Titan
SEC Form 424B5 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology, Inc. (NASDAQ:NXL) Shares Acquired by Geode Capital Management LLC - Defense World
SEC Form 424B4 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology (NXL) Seeks FDA Feedback for Gen-2 SYNC Syste - GuruFocus
Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design - marketscreener.com
Nexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC System Targeting Cognitive Disorders - Nasdaq
Nexalin Technology Initiates FDA Q-Submission Process for - GlobeNewswire
FDA Fast-Tracks Nexalin Gen-2 SYNC Review for Alzheimer's Treatment | NXL Stock News - Stock Titan
Nexalin Technology (NASDAQ:NXL) Shares Down 0.5% – Time to Sell? - Defense World
International Milestone for Anxiety-Insomnia Neurostim Company - Sleep Review
Nexalin Technology files $50M common stock offering - MSN
Nexalin Technology (NXL) Gains Approval for Clinical Trial in Br - GuruFocus
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewswire
Nexalin Technology Inc Stock (NXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):